2016 Towards an HIV Cure Symposium
16 & 17 July 2016 | Durban, South Africa

  • Symposium
  • Programme Committee

The IAS and the Towards an HIV Cure Stakeholder’s Advisory Board organized the fifth annual Towards an HIV Cure Symposium in Durban, South Africa on 16 & 17 July 2016, immediately preceding the 21st International AIDS Conference (AIDS 2016).

The symposium continued to showcase the latest research in HIV cure, aligned with the research priorities outlined in the 2016 Global Scientific Strategy, but also provided a platform for presenting the progress of the initiative working groups and creating a fertile setting for dialogue with the broader community, through abstract driven sessions, poster exhibition sessions and roundtable discussions. 

The symposium was be co-chaired by Prof. Françoise Barré-Sinoussi, Dr. Steven Deeks, Professor of Medicine at the University of California, San Francisco (UCSF), and Prof. Sharon Lewin, Director of the Doherty Institute for Infection and Immunity, University of Melbourne.

Symposium Objectives

  • Provide an opportunity for scientists who are working on HIV cure to share ideas, debate, and network among their peers;
  • Develop knowledge on the priorities that future research must address in order to tackle HIV persistence in patients on ART;
  • Accelerate research on viral reservoirs  and latency as the way towards achieving a cure for HIV infection;
  • Promote increased investments in HIV/AIDS cure research;
  • Provide a platform for information-sharing between scientists, clinicians, funders, media and members of civil society.

2016 Symposium Programme Committee

Scientific Coordination

  • Anna Laura Ross

Symposium Logistics

  • Rosanne Lamplough


The scientific program of 2016 Towards an HIV Cure Symposium has been reviewed by the American Medical Association and approved for a maximum of 9.5 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity. One credit may be claimed for each hour of participation in approved sessions.

All relevant disclosures of financial relationships with commercial entities have been provided by the programme faculty and can be accessed here.


Symposium material

  • Related documents
  • Day 1
  • Day 2
  • Poster Exhibition
  • Multimedia
The abstracts presented at the 2016 Towards an HIV Cure Sympsoium are published in a supplement of the Journal of Virus Eradication and can be found in the abstract portal here.

Opening Session

Keynote Address: Progress and Challenges in HIV Cure Research
Anthony Fauci, National Institute of Allergy and Infectious Diseases, NIH, United States

Presentation | Audio

Community Speaker: Moving Towards AIDS Cure: Community Partnerships
Gethwana Mahlase, COMOSAT NGO, South Africa

Presentation | Audio

Oral Abstract Session 1: Ethics and Social Sciences in HIV Cure Research

Invited Speaker: Identifying Key Drivers of the Impact of an HIV Cure Intervention in Sub-Saharan Africa
Andrew Phillips, University College London, United Kingdom

Presentation | Audio

OA1-1: Unanticipated participant benefits in HIV cure clinical research: A qualitative analysis
Adam Gilbertson, University of North Carolina at Chapel Hill, United States

Presentation | Audio

OA1-2: Ethical and social implications of proposed HIV cure research: stakeholder perspectives from South Africa
Ciara Staunton, Stellenbosch University, South Africa

Presentation | Audio

OA1-3: Factors Affecting Participation in HIV Cure-Related Research in the United States: Implications for Effective and Ethical Implementation
Karine Dubé, UNC Gillings School of Global Public Health, United States

Presentation | Audio

Special Session: Paediatric HIV Cure Research

Invited Speakers: Neonatal and paediatric immunology relevant to HIV persistence
Deena Gibbons, King’s College London, United Kingdom
Nigel Klein, University College London, United Kingdom

Presentation | Audio

Roundtable: Research priorities in paediatric HIV cure


Moderator: Jintanat Ananworanich
US Military HIV Research Program, United States

Paolo Rossi
University of Rome, Italy

Thanyawee Puthanakit
Chulalongkorn University, Thailand

Barbara Kingsley
HIV Activist, South Africa

Diana Finzi
National Institute of Allergy and Infectious Diseases, NIH, United States

Caroline Tiemessen
National Institute for Communicable Diseases, South Africa

The abstracts presented at the 2016 Towards an HIV Cure Sympsoium are published in a supplement of the Journal of Virus Eradication and can be found in the abstract portal here.

Oral Abstract Session 2: HIV Latency and Reversal Strategies

Invited Speaker: Addressing key gaps in cure research through identification and treatment of hyperacute HIV infection in a resource-limited setting
Thumbi Ndung’u, University of KwaZulu-Natal, South Africa

Presentation | Audio

OA2-1: Frequent and 'burst-like' reactivation from latency in SIVmac239M infected macaques
Miles Davenport, Kirby Institute for Infection and Immunity, Australia

Presentation | Audio

OA2-2: Cell-associated HIV-1 unspliced RNA level predicts both time to virological suppression and duration of post-treatment virological control in patients treated with temporary early ART
Alexander Pasternak, Academic Medical Center of the University of Amsterdam, Netherlands

Presentation | Audio

OA2-3: BCL-2 antagonism decreases HIV replication and infected cell survival in acute in vitro infection
Andrew Badley, Mayo Clinic, Infectious Diseases, United States

Presentation | Audio

OA2-4: Enhancing HIV-1 Virion Tethering by BST2/Tetherin Sensitizes Productively and Latently Infected T cells to ADCC Mediated by Broadly Neutralizing anti-HIV Antibodies
Éric A. Cohen, Institut de Recherches Cliniques de Montréal and Université de Montréal, Canada

Presentation | Audio

OA2-5 LB: No Evidence of Ongoing Replication in Tissue Compartments During Combination Antiretroviral Therapy
Giorgio Bozzi, NCI NIH at Frederick, United States

Presentation | Audio

Oral Abstract Session 3: Novel Strategies for HIV Cure

Invited Speaker: How Can Oncology Help HIV Cure Strategies?
Olivier Lambotte, APHP - Hôpital Bicêtre, France

Presentation | Audio

OA3-1: Allogeneic Stem Cell Transplantation in HIV-1 Infected Individuals; the EpiStem Consortium
Annemarie Wensing, University Medical Center Utrecht, Netherlands

Presentation | Audio

OA3-2: CCR5 Gene Edited Cells Traffic to Viral Reservoir Tissues and Undergo SHIV-Dependent Positive Selection in Nonhuman Primates
Christopher Peterson, Fred Hutchinson Cancer Research Center, United States

Presentation | Audio

OA3-3: Combinatorial CRISPR/Cas9 approaches targeting different steps in the HIV life cycle can prevent the selection of resistance
Monique Nijhuis, University Medical Center Utrecht, Netherlands Abstract

Presentation | Audio

OA3-4 LB: Elimination of HIV-1 latently infected cells by PKC agonist gnidimacrin alone and in combination with a histone deacetylase inhibitor
Li Huang, Duke University Medical Center, United States

Presentation | Audio

OA3-5 LB: Effect of vorinostat, hydroxychloroquine and maraviroc combination therapy on viremia following treatment interruption in individuals initiating ART during acute HIV infection
Jintanat Ananworanich, US Military HIV Research Program, United States

Presentation | Audio

Roundtable: Bridging Biomedical Research and Social Sciences Towards an HIV Cure


Chair: Judith Auerbach
University of California, San Francisco, United States

Moses Supercharger Nsubuga
Joint Clinical Research Centre, Uganda

Jerome Singh
Nelson R. Mandela School of Medicine, South Africa

Peter Newman
University of Toronto, Canada

Monique Nijhuis
University Medical Center Utrecht, Netherlands


Oral Abstract Session 4: Immunology of HIV Persistence

Invited Speaker: The Role of B Cell Follicles in HIV Replication and Persistence
Elizabeth Connick, University of Arizona, United States

Presentation | Audio

OA4-1: Heterodimeric IL-15 induces effector cell activation and trafficking to the Germinal Centers of SIV infected Macaques
Barbara Felber, National Cancer Institute at Frederick, United States

Presentation | Audio

OA4-2: HIV Persists in Colon and Blood CCR6+CD4+ T-Cells during ART
Jean-Pierre Routy, McGill University Health Centre, Canada

Presentation | Audio

OA4-3: PD-1 blockade combined with ART improves SIV-specific CD8 T cell function and enhances control of pathogenic SIV after ART interruption
Rama Rao Amara, Emory University, Yerkes National Primate Research Center, United States

Presentation | Audio

OA4-4: Latency reversing agents induce HIV-1 protein expression in latently infected cells for cytotoxic T-lymphocyte antiviral recognition and killing
Julia G. Prado, AIDS Research Institute IrsiCaixa, Spain

Presentation | Audio

OA4-5 LB: SIV persistence in ART-treated infant rhesus macaques
Ann Chahroudi, Emory University, United States

Presentation | Audio

Closing Session

Closing Lecture:   Development and Reversal of T Cell Exhaustion
John Wherry, University of Pennsylvania, United States

Presentation | Audio

IAS/ANRS HIV Cure Young Investigator Award Ceremony


The abstracts presented at the 2016 Towards an HIV Cure Sympsoium are published in a supplement of the Journal of Virus Eradication and can be found in the abstract portal here.

Viral diversity, phylogenetics and phylodynamics

P1: Analysis of Intra-patient, Full Length HIV gag Sequences Identifies Regions of Variability
Elizabeth Anderson
National Cancer Institute at Frederick, United States

Antibody diversity and function

P2: Increased interferon-alphaactivity may contribute to defects of B cells and antibody production caused by HIV-1 infection
Martyn French
University of Western Australia, Australia

Reverse transcription and integration

P3: HIV infected patients with exceptional TCD4+ recovery during effective HAART present a distinct T CD4+ differentiation pattern, higher CD31neg naïve cells and a smaller HIV reservoir
Santiago Perez-Patrigeon
INCMNSZ, Infectious Diseases, Mexico

HIV-1 controllers (including post-treatment controllers)

P4: Post-treatment Control or Treated Controllers? The impact of ART on time to viral rebound in recent seroconverters
Genevieve E. Martin
University of Oxford, United Kingdom

P5: Identification of different HIV-controller phenotypes: looking for the right model of functional cure
Beatriz Dominguez-Molina
Institute of Biomedicine of Seville, Virgen del Rocio University Hospital, Spain

P6: HIV Virological Controllers in an African Cohort
Yumna Moosa
CAPRISA, South Africa

Correlates of immune protection

P7: Presence of HIV-1C broadly neutralizing antibodies in pregnancy and at delivery
Takafira Mduluza
University of Zimbabwe, Zimbabwe

Viral mechanisms of HIV/SIV persistence and latency

P8: IFNα activates latent HIV-1 in non-proliferating latently infected T-cells
Renee Marije van der Sluis
Doherty Institute for Infection and Immunity, University of Melboure, Australia


P9: HIV-1 Disrupts Mitochondrial Dynamics: Induces Fission and Mitophagy to Attenuate Apoptosis in Astrocyte (Late Breaker)
Diego Sebastian Ojeda
INBIRS, Microbiologia, Argentina

Host cellular factors and latency

P10: The interferon-inducible restriction factor TRIM22 contributes to HIV-1 latency
Filippo Turrini
Vita-Salute San Raffaele University, Italy

P11: Identification of a new host cell HDAC complex that controls HIV latency through direct binding to the core promoter
Emmanuelle Wilhelm
Université de Sherbrooke, Canada

Cellular and tissue reservoirs of HIV/SIV

P12: Persistence of HIV DNA in Seminal Plasma Fraction after ART among Men who have Sex with Men and Transgender Women in the Thailand Test &Treat Cohort
Eleanore Chuang
University of Hawaii, United States


P13: Memory CD4+ T cells expressing HLA-DR contribute to HIV persistence during prolonged ART
Eunok Lee
The Westmead Institute for Medical Research, University of Sydney, Australia


P14: Effect of Substances of Abuse on HIV DNA Decay during Antiretroviral Therapy Started During Early HIV Infection
Sara Gianella
University of California San Diego, United States

P15: Is the lung a site of productive HIV infection that persists through ART?
David Russell
Cornell University, United States

P16: Whole-body SPECT in Vivo Imaging reveals delayed reconstitution of lymph-nodes, but not spleen, CD4 pools in long-term cART treated animals (Late Breaker)
Michele Di Mascio
Division of Clinical Research, NIAID, NIH, United States

Measurement of HIV/SIV reservoirs

P17: HIV proviral DNA quantification in a cohort of Japanese patients on long-term ART
Kamelia Stanoeva
Kumamoto University, Center for AIDS Research, Japan


P18: Initiation of ART within 24-48 hours of birth following in utero HIV infection - the Ucwaningo Lwabantwana Study
Julia Roider
University of Oxford, United Kingdom


P19: Quantification and correlates of the replication competent HIV-1 latent viral reservoir in a virally suppressed Ugandan population
Jessica L. Prodger
National Institute of Allergy and Infectious Diseases, NIH, United States

Targeting and eradication of reservoirs

P20: Sirtuin1 Inhibitor Nicotinamide disrupts HIV-1 Latency
Sadia Samer
Federal University of Sao Paulo, Brazil

P21: T regulatory cell depletion in controller macaques reactivates SIV and boosts CTLs
Tianyu He
University of Pittsburgh, United States

P22: Development of DOUBLE NICKASE CRISPR Aganist Latently Infected Human Immunodeficency Virus (HIV)
Oluwaseun Ayodeji Ishola
Advanced medical and dental institute, Universiti Sains Malaysia, Malaysia


P23: Understanding the effects of latency reversing agents on HIV RNA splicing - implications for latency reversal
Talia M. Mota
University of Melbourne, Doherty Institute for Infection and Immunity, Australia

P24: Thalidomide Reverses Latency of HIV-1 Provirus
Sadia Samer
Federal University of Sao Paulo, Brazil

P25: Targeting HSF1-mediated stress response can enhance Hsp90 inhibitor-induced suppression of HIV-1 reactivation from latency
Alexander Kabakov
Biomedical Research Center, Russian Federation

P26: A novel assay to evaluate the response of patient-derived virus to latency-reversing agents ex vivo
Hao Lu
Peter Doherty Institute, University of Melbourne, Australia

P27: Therapeutic immune recovery prevents emergence of CXCR4-tropic HIV-1
Thomas Klimkait
University of Basel, Switzerland


P28: Dendritic cells programmed by inflammatory mediators can effectively induce both the immunologic 'kick' and 'kill' of latent HIV-1
Jan Kristoff
University of Pittsburgh, United States

P29: In vivo analysis of the effect of panobinostat on cell-associated HIV RNA and DNA levels, and latent HIV infection
Perry Tsai
University of North Carolina at Chapel Hill, United States

P30: Maraviroc administration is associated to reversion of latent HIV-1 through NFkB in ART suppressed patients (Late Breaker)
Santiago Moreno Guillén
Hospital Ramón y Cajal, Spain

Acute and early infection

P31: Systematic Review of the Current Literature on Structured Treatment Interruptions in HIV-infected Patients Receiving Antiretroviral Therapy - Implications for Future HIV Cure Trials
Melanie Stecher
University Hospital of Cologne, Germany

P32: Alarmin IL-33/ST2 pathway as an inductor of T-cell dependent response in acute and early HIV-infected patients
Jean-Pierre Routy
McGill University Health Centre, Canada

Novel approaches in Immunotherapeutics (including bnAbs and anti-inflammatory mediators)

P33: A novel bispecific immunoadhesin displays enhanced breadth and potency against diverse HIV-1 subtypes in vitroand in humanized mice
Xilin Wu
AIDS Institute, The University of Hong Kong, Hong Kong

P34: Novel Conserved Element HIV/SIV DNA Vaccines Maximize Breadth and Magnitude of Immune Response
Barbara K. Felber
National Cancer Institute at Frederick, United States


Targeting HIV persistence during ART (cure strategies)

P35: Therapy with The Immunomodulatory Agent Pomalidomide Does Not Lead To Changes In HIV-1 Viral Populations In Vivo
Sarah A. Watters
University College London, United Kingdom

P36: Dose-dependent effects of HDACi on T cell activation and HIV latency reversal
Xiao Mei T. Kuang
Simon Fraser University, Canada

P37: Novel pathways of Tat expression identify new targets for reactivation of latent HIV-1
Michelle Lee
University of Melbourne at the Peter Doherty Institute for Infection and Immunity, Australia

P38: Small molecule inhibitors of BAF; a new family of compounds in HIV-1 latency reversal
Elisa De Crignis
Erasmus MC, Netherlands

P39: Novel activators and suppressors of latent HIV-1 from natural products
Ian Tietjen
Simon Fraser University, Canada

P40: A systems dynamics approach to identifying novel HIV treatments
Hua Yang
Cooper Human Systems, United States


P41: Vitamin D level in cART treated patients is critical for HIV reservoir size
Christine Rouzioux
Necker Hospital, France

Therapeutic vaccines

P42: Characterization ofMonocyte-Derived Dendritic Cells Used in Immunotherapy for HIV-1-infected Individuals
Lais Teodoro da Silva
Faculdade de Medicina da Universidade de Sao Paulo, Brazil

P43: siRNA based TLR7/8 activation, MHC class I recycling from endosome and cross presentation of HIV-1 antigen for elevated CD8+ response: An approach for intracellular vaccine
Birendra Gupta
Tribhuvan University, Nepal

P44: Volunteer motivators for participating in HIV vaccine clinical trials in Nairobi, Kenya
Borna Achieng Nyaoke
KAVI-Institute of Clinical Research, University of Nairobi, Kenya

P45: HIV-tat fused to the oligomerisation domain of the c4-binding protein is highly immunogenic and controls EcoHIV challenge in mice
Khamis Tomusange
University of Adelaide, Australia

Novel animal/virus models for vaccine, cure research, and inhibitor development

P46: A nonhuman primate model of fully MHC-matched allogeneic stem cell transplantation to study HIV reservoir clearance (Late Breaker)
Ben Burwitz
Oregon Health & Science University, Vaccine & Gene Therapy Institute, United States


Animal models of latency reservoirs and eradication

P47: Immuno-PET/CT imaging reveals differences in virus and CD4+ cell localization in SIV infected rhesus macaques treated with an anti-α4β7 mab
James Arthos
National Institute of Allergy and Infectious Diseases, NIH, United States

Acute and early infection

P48: Faster restoration of CD4:CD8 ratio during the first 12 weeks of ART initiated at early HIV infection compared with ART initiated at chronic infection in the same patients
Alexander Pasternak
Academic Medical Center of the University of Amsterdam, Netherlands


P49: Using ddPCR to Assess Persistence of HIV DNA Reservoirs in Perinatally Infected Infants Treated with cART Before or After 12 Months of Age
Priya Soni
UCLA - David Geffen School of Medicine, United States


P50: Central nervous system impact of vorinostat, hydroxychloroquine and maraviroc combination therapy followed by treatment interruption in individuals treated during acute HIV infection (Late Breaker)
Eugene Kroon
SEARCH, The Thai Red Cross AIDS Research Centre, Thailand

Ethical issues in clinical trials and treatment strategies

P51: HIV patients and caregivers viewpoints towards participation to future HIV Cure-related clinical trials - results from the second part of the French ANRS-APSEC survey
Marie Suzan-Monti
INSERM, UMR_S 912, France


P52: How to keep high-risk early-phase HIV cure and long-term remission studies ethical: classifying candidate solutions
Nir Eyal
Harvard TH Chan School of Public Health, United States

Social and behavioural concepts and theories

P53: Perceptions of HIV remission (“cure”) trials and trial intentions among potential participants treated in acute HIV infection
Thidarat Jupimai
SEARCH, The Thai Red Cross AIDS Research Center, Thailand

P54: How curing HIV could influence stigma: a qualitative analysis of men who have sex with men in Guangzhou, China
Feng Wu
UNC Project-China, China


Community engagement in research and research dissemination

P55: “I can coexist with HIV”: a qualitative study of perceptions of HIV "cure" among people living with HIV in Guangzhou, China
Feng Wu
UNC Project-China, China


Ethical aspects and standards, including with respect to research, clinical services, public health policy and programmes, and professional conduct

P56: Is there an implementation ethics to HIV cure-related research?
Karine Dube
University of North Carolina at Chapel Hill, United States

P57: HIV Cure research: a survey of Australian people living with HIV onperspectives, perceived benefits and willingness to participate in trials
Jennifer Power
La Trobe University, Australia

P58: Challenges in developing an educational video on HIV Cure research
Ciara Staunton
Stellenbosch University, Centre for Medical Ethics and Law, South Africa


P59: Interrupting HIV Treatment in Cure Research: Scientific and Ethical Considerations
Jeremy Sugarman
Johns Hopkins University, United States

Photo gallery


With the support of: